NewsFlash »

Natco Pharma Applies To Sell Generic Lenalidomide In The U.S. – The Indian drug company Natco Pharma filed a request with the Food and Drug Administration to market generic lenalidomide before Celgene’s patents on Revlimid (lenalidomide) expire in 2026. Revlimid is approved in the U.S. for the treatment of multiple myeloma as well as a collection of blood disorders called myelodysplastic syndromes. Investment analysts have speculated that the patent that extends Revlimid’s exclusivity from 2019 to 2026 is being challenged. Despite this application, the sale of generic lenalidomide is not likely for at least several years. Celgene plans to sue Natco for patent infringement, which would automatically result in a 30-month delay of Natco’s application to sell generic lenalidomide in order to settle the lawsuit. For more information, see the Dow Jones article.

Clinical Insights Education Program – The Multiple Myeloma Research Foundation (MMRF) is sponsoring an education program about multiple myeloma clinical insights. The event will be held on September 8 in St. Louis. Myeloma experts Drs. Ravi Vij, Todd Zimmerman, Keith Stockerl-Goldstein, Shaji Kumar, and David Vesole will speak about the latest advances in frontline therapy, stem cell transplants, relapsed and refractory myeloma, supportive care, and clinical trials. There will also be a question and answer session. Registration will begin at 10 a.m., and the program will conclude at 3 p.m. A similar program will be held in Houston on October 15. For more information about the St. Louis program or to register, please see the MMRF website.

For a more detailed listing of myeloma-related events, please check the Myeloma Beacon Events Calendar.